Process of making derivatives of substituted morpholines

Patent metadata

Field	Value
Publication number	US-11964951-B2
Application number	US-202318206953-A
Country	US
Kind code	B2
Filing date	Jun 7, 2023
Priority date	Mar 18, 2022
Publication date	Apr 23, 2024
Grant date	Apr 23, 2024

Abstract

Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof. Further provided are methods of making derivatives and prodrugs of substituted morpholines having the following chemical structure:

First claim

The invention claimed is:

1. A method of manufacturing a morpholine derivative of formula Ilf or a pharmaceutically acceptable salt thereof, the method comprising:
(a) reacting a compound of formula

with (S)-(+) epichlorohydrin to form a chlorohydrin compound of formula

(b) contacting the chlorohydrin compound with a base and a phase transfer catalyst to form an epoxide compound of formula

(c) contacting the epoxide compound with a base and a compound of formula:

(Ia) to form a diol compound of formula

(d) contacting the diol compound with a base followed by addition of a sulfonyl halide compound to form an intermediate sulfonate of formula

(IIa'), wherein Z is a sulfonyl leaving group, that cyclizes in situ to form an N-benzyl protected morpholine compound of formula

(e) forming the HCl salt of the compound of formula (IIb) and recrystallizing it to afford the highly pure (S)-enantiomer as an HCl salt;
(f) converting the HCl salt of compound (IIb) to the free base;
(g) contacting the N-benzyl protected morpholine compound with a chloroformate of formula:

(Ic); to form an intermediate N-benzyl chlorocarbamate salt of formula

that loses benzyl chloride upon heating to give a compound of formula

(h) addition of the chlorocarbamate compound to a metal salt of an amino acid derivative of formula

wherein the amino acid derivative has been pretreated with a metal compound, to form a protected amine of formula

and,
(i) contacting the protected amine with an acid to provide the morpholine derivative (IIf) as an acid salt:

wherein R 1 is C 1 -C 6 alkyl, aryl, or heteroaryl; each R 2 is independently selected from F, Cl, Br, I, CN, NO 2 , C 1 -C 6 alkyl, aryl, heteroaryl, or heterocycloalkyl; R 3 is a C 1 -C 6 alkyl, R 4 is a the C 1 -C 6 alkyl, R 5 is an amino protecting group; and n is 0, 1, 2, 3, or 4.

2. The method according to claim 1 , wherein the phase transfer catalyst is tetrabutylammonium hydrogen sulfate.

3. The method according to claim 1 , wherein a phase transfer catalyst is utilized in step (d).

4. The method according to claim 3 , wherein the phase transfer catalyst is benzyltriethylammonium chloride.

5. The method according to claim 4 , wherein the product contains greater than 60% of the (S) enantiomer and the (S)—HCl salt may be crystallized to give the HCl salt with greater than 90% of one enantiomer.

6. The method according to claim 1 , wherein the sulfonyl halide selected from the group consisting of p-toluenesulfonyl chloride (tosyl chloride), brosyl chloride, nosyl chloride, and mesyl chloride.

7. The method according to claim 6 , wherein the sulfonyl halide compound is p-toluenesulfonyl chloride.

8. The method according to claim 1 , wherein cyclization is performed using NaOH.

9. The method according to claim 1 , wherein the crude product chlorocarbamate compound formed step (g) is washed with an alkane solvent, evaporated, or treated with triethylamine to remove benzyl chloride byproduct before performing the next step.

10. The method according to claim 1 , wherein the metal salt of step (h) is a cesium salt.

11. The method according to claim 1 , wherein the metal compound of step (h) is cesium carbonate.

12. The method according to claim 1 , wherein step (a) further comprises an organic solvent.

13. The method according to claim 12 , wherein step (a) further comprises heating to a temperature of at least 30° C.

14. The method according to claim 1 , wherein step (b) is performed at room temperature.

15. The method according to claim 1 , wherein R 1 is —CH 3 or —CH 2 CH 3 .

16. The method according to claim 1 , wherein each R 2 is independently selected from -F, -Cl, -Br, -I, or C 1 -C 6 alkyl.

17. The method according to claim 1 , wherein R 3 is —CH 3 or isopropyl.

18. The method according to claim 1 , wherein R 4 is isopropyl.

19. The method according to claim 1 , wherein R 5 is tert -butoxycarbonyl (Boc).

20. The method according to claim 1 , wherein n is 0.

21. The method according to claim 1 , wherein the morpholine derivative from step (i) has the following formula

or a pharmaceutically acceptable salt thereof.

22. The method according to claim 1 , wherein the morpholine derivative from step (i) has the following formula:

or a pharmaceutically acceptable salt thereof.

23. The method according to claim 1 , wherein the morpholine derivative from step (i) has the following formula:

or a pharmaceutically acceptable salt thereof.

Assignees

• Supernus Pharmaceuticals Inc

Inventors

• Sun Yanjun
• Nallaganchu Bhaskara Rao
• Olson Gary L

Classifications

• C07C309/66

  Methanesulfonates · CPC title

• C07C309/73

  to carbon atoms of non-condensed six-membered aromatic rings · CPC title

• C07D265/30 Primary

  not condensed with other rings · CPC title

• C07C217/34 Primary

  by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms · CPC title

• C07B2200/07

  Optical isomers · CPC title